CONTENTS

CENTENNIAL PERSPECTIVE

SHORT COMMUNICATIONS
The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil. Hei-Young Ku, Hee-Jeong Ahn, Kyung-Ah Seo, Hyunmi Kim, Minkyung Oh, Soo Kyung Bae, Jae-Gook Shin, Ji-Hong Shon, and Kwang-Hyeon Liu .................. 986
Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro. Ryan H. Takahashi, Onkar S. Bains, Tom A. Pfeifer, Thomas A. Grigliatti, Ronald E. Reid, and K. Wayne Riggs ..................... 991

ARTICLES
Identification of Human Liver Cytochrome P450 Isoforms Involved in Autoinduced Metabolism of the Antiangiogenic Agent (Z)-5-{[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrrole-3-carboxylic Acid (TSU-68). Ryuichi Kitamura, Hisae Asanoma, Sekio Nagayama, and Masaki Otagiri ..................... 1003
Hepatic Uptake and Excretion of (−)-N-(2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidin-4-yl])-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans. Ken-ichi Umehara, Megumi Iwai, Yasuhiro Adachi, Takafumi Ikawa, Takashi Usui, and Hitotaka Kaminura ............... 1030
Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats. Doreen Mitschke, Andreas Reichel, Gert Fricker, and Ursula Moening .................................................. 1039
Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction. Niresh Hariparsad, Brian A. Carr, Raymond Evers, and Xiaoyan Chu ................................................................. 1046
The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT)

CONTINUED ON NEXT PAGE

Drug Metabolism and Disposition (ISSN 0090-9556) is published monthly (one volume per year) by the American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995; e-mail: info@aspet.org; Web site: http://www.aspet.org Periodicals postage paid at Bethesda, MD and at additional mailing offices. POSTMASTER: Send address changes to Drug Metabolism and Disposition, 9650 Rockville Pike, Bethesda, MD 20814-3995. Subscription rates: U.S.: $374.00 for institutions and $195.00 for non-ASPET members. Outside the U.S.: $448.00 for institutions and $269.00 for non-ASPET members. Single copy: $36.00. GST Tax Number for Canadian subscribers: BN:13489 2350 RT. Indexed or abstracted by Biochemistry & Biophysics Citation Index®, Biological Abstracts, BIOSIS Previews Database, BIOSCIences Information Service, Current Awareness in Biological Sciences, Current Contents/Life Sciences, EMBASE/Excerpta Medica, Index Medicus, International Pharmaceutical Abstracts, Medical Documentation Service®, Reference Update®, Research Alert®, Science Citation Index®, Scisearch®, and SIC Data Bases. Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics. All rights reserved. Printed in the U.S.A.